Nervous Disorder TRIZ Cases

A homeopathic injection agent administered in the earlobe achieves immediate smoking cessation.

ALZ-801 valine prodrug reduces plasma p-tau to treat COVID-19 associated neurological symptoms.

Heat-killed Mycobacterium vaccae immunization reduces stress-induced neuroinflammation and cocaine craving without complex pharmacological administration.

Targeting LAR phosphatases reduces amyloidogenic processing while preserving secretase function, avoiding side effects from direct inhibition.

Patient-derived hepatocytes measure biomolecule concentrations to identify therapeutic agents and diagnose Parkinson's disease.

A prostaglandin mimetic stimulates prostacyclin release to counteract gastrointestinal damage from non-selective NSAIDs.

BOL-148 compounds reduce OCD symptoms faster than serotonin reuptake inhibitors, addressing treatment resistance.

Epitope-specific antibodies target pathogenic protofibrils to reduce CNS inflammation while clearing toxic aggregates.

Prunus cerasoides extract activates neuroglobin, reducing cerebral infarction size and side effects.

A heterocyclic compound inhibits monoamine reuptake to deliver rapid therapeutic effects.

Antibodies neutralize interferon-alpha and omega to reduce disease symptoms while sparing interferon-beta signaling.

Culturing human pluripotent stem cells in suspension to form embryonic bodies that differentiate into mesenchymal stem cells.

Two-stage vacuum drying removes residual solvents from Ubrogepant acetonitrile-water solvate, achieving greater than 99.5% purity.

Enteric coated endoxifen citrate resolves bipolar I suicide risk by maintaining stable concentrations through PKC inhibition.

Partial metallation of recombinant metallothionein creates defined redox states that scavenge free radicals while balancing intracellular metal ion levels.

Dual-targeting peptide therapy reduces APP-Tau complex formation and cognitive decline in Alzheimer's models.

VRAC modulators block ion channels to re-sensitize chemotherapy-resistant cancer cells, reversing drug resistance and restoring treatment response.

Segmenting inhibitor functions into distinct Kunitz domains within one polypeptide achieves multi-target coverage while eliminating off-target side effects.

Variant PD-L1 polypeptides resolve specificity trade-offs by reducing PD-1 binding while maintaining B7-1 affinity for selective T cell modulation.

A mixed salt oxybate composition maintains therapeutic efficacy while reducing sodium intake.

Malononitrilamides treat central nervous system trauma without corticosteroid side effects.

Oral LSD1 inhibitor reduces immune infiltration and demyelination, overcoming parenteral limitations.

RAR-CLA supplementation improves cognitive scores in aging males by enriching cis-9, trans-11 isomers to resolve low purity trade-offs.

Hexahydroxybenzophenone compounds reduce toxic side effects while maintaining high efficacy against HIV, herpes virus, and cancer cells.

Combining NMN, NR, and PEITC modulates multiple upstream pathways to reduce neurotoxic ratios and regulate microglia activity.

Block copolymer prodrugs traverse the blood-brain barrier, reducing systemic exposure and adverse reactions.

A connection initialization request message triggers re-routing from packet switched to circuit switched domains.

A zinc finger-like peptide with sequence RRSSSCK downregulates protein aggregation.

Agonist antibodies bind TREM2 receptors to recruit oligodendrocyte precursor cells and clear myelin debris.

Genetically corrected iPSCs generate neural precursor cells expressing ASPA to restore enzymatic activity in the brain.

Poloxamer surfactants create micellar structures that protect cannabinoids from gastric lipase degradation and first-pass metabolism.

Dopamine D4 receptor antagonists stop Alzheimer's progression and sustain therapeutic benefits.

Menthol and Icilin depress neuronal activity via TRPM8 channels, preventing excitotoxicity without the side effects of glutamate antagonists.

A topical sustained release composition delivers non-steroidal anti-inflammatory drugs through the skin to provide localized pain relief.

Differential centrifugation isolates nano-sized exosomes from coffee, ginkgo-biloba, and ginseng to overcome size limitations of traditional extracts.

New anesthetic agents modulate GABAa receptors to induce anesthesia while reducing hemodynamic side effects and toxicity in patients.

Saponins and gum Arabic encapsulate ginger oleoresin in micelles, resolving poor water solubility while maintaining bioefficacy.

Antibodies targeting hTau-pT217 replace complex imaging with plasma assays, resolving the trade-off between diagnostic sensitivity and patient invasiveness.

Umbilical cord blood nucleated cells eliminate immunopathological risks by avoiding HLA-typing while delivering therapeutic efficacy.

AT1 receptor blockers reduce sleep latency and increase nREM sleep while preserving REM architecture.

Antibodies bind FcRn to block albumin interaction, reducing serum half-life of toxins.

Bispecific antibody binds interleukin-17A and interleukin-23 to block pro-inflammatory cytokine activity.

Gluconate compositions block CLC-3 chloride channels to treat neonatal seizures, avoiding the exacerbation caused by conventional antiepileptic drugs.

Antibodies binding Annexin-1 modulate T cell activation to treat refractory obsessive compulsive disorder without adverse cytotoxic effects.

Ultrahigh potency sweeteners mask cannabinoid taste without polar solvents, enabling low ethanol levels for pediatric stability.

Combining 5-HT6 receptor antagonists with acetylcholinesterase inhibitors enhances cognitive performance in patients.